4//SEC Filing
Browne L Daniel 4
Accession 0001209191-17-062450
CIK 0001479290other
Filed
Nov 23, 7:00 PM ET
Accepted
Nov 24, 4:06 PM ET
Size
6.0 KB
Accession
0001209191-17-062450
Insider Transaction Report
Form 4
Browne L Daniel
DirectorCEO and President
Transactions
- Sale
Common Stock
2017-11-22$24.94/sh−7,600$189,570→ 133,188 total
Holdings
- 409(indirect: See footnote)
Common Stock
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Browne.
- [F2]The price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.70 to $25.15. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.
Documents
Issuer
Revance Therapeutics, Inc.
CIK 0001479290
Entity typeother
Related Parties
1- filerCIK 0001597583
Filing Metadata
- Form type
- 4
- Filed
- Nov 23, 7:00 PM ET
- Accepted
- Nov 24, 4:06 PM ET
- Size
- 6.0 KB